User profiles for "author:Edward Neuberger"

Edward Neuberger

SeaGen
Verified email at seagen.com
Cited by 53

[HTML][HTML] Work productivity outcomes associated with ocrelizumab compared with other disease-modifying therapies for multiple sclerosis

EE Neuberger, IM Abbass, E Jones… - Neurology and Therapy, 2021 - Springer
Objective This study evaluated work and activity impairment in patients with multiple
sclerosis (MS) treated with ocrelizumab (OCR) versus other disease-modifying therapies …

Economic value of pharmacogenetic testing for cancer drugs with clinically relevant drug-gene associations: a systematic literature review

F Faruque, H Noh, A Hussain, E Neuberger… - Journal of managed …, 2019 - jmcp.org
BACKGROUND: Pharmacogenetic testing can provide predictive insights about the efficacy
and safety of drugs used in cancer treatment. Although many drug-gene associations have …

Baloxavir vs Oseltamivir: Reduced Utilization and Costs in Influenza.

E Neuberger, C Wallick, D Chawla… - American Journal of …, 2022 - search.ebscohost.com
OBJECTIVES: To determine whether baloxavir use is associated with lower health care
resource utilization (HCRU) and costs for secondary influenza complications post treatment …

Cost-effectiveness of cannabidiol adjunct therapy versus usual care for the treatment of seizures in Lennox-Gastaut syndrome

EE Neuberger, JJ Carlson, DL Veenstra - Pharmacoeconomics, 2020 - Springer
Background Cannabidiol (CBD) is a novel therapy for the treatment of Lennox-Gastaut
Syndrome (LGS), a rare, treatment-refractory epileptic encephalopathy. Two pivotal trials …

[PDF][PDF] Antiviral Use and Health Care Use Among US Patients With Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016‐2019

EE Neuberger, TM To, A Seetasith… - ACR Open …, 2022 - Wiley Online Library
Objective Patients with rheumatoid arthritis (RA) are vulnerable to severe complications of
influenza. We assessed whether health care resource use (HRU) and costs differed …

[HTML][HTML] Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer

PA Kaufman, E Neuberger, NRM Schwartz… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Background Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed
therapy approved in combination with trastuzumab and capecitabine for use in patients with …

[HTML][HTML] Worse outcomes and higher costs of care in fibrostenotic Crohn's disease: a real-world propensity-matched analysis in the USA

M Dehghan, G Wong, E Neuberger… - BMJ Open …, 2021 - bmjopengastro.bmj.com
Background Patients with Crohn's disease (CD) may develop fibrostenotic strictures. No
currently available therapies prevent or treat fibrostenotic CD (FCD), making this a critical …

1345. Patient Perspectives and Journey with Influenza and Seeking Care from US National Survey

N Way, A Martin, C Wallick, E Neuberger… - Open Forum Infectious …, 2021 - ncbi.nlm.nih.gov
Background In the 2017-2018 influenza season, 49 million people in the US presented with
influenza symptoms, resulting in substantial morbidity, mortality, and a significant humanistic …

Evaluating Methods to Estimate United States Multiple Sclerosis Prevalence from Administrative Health Claims Data

E Neuberger - 2019 - digital.lib.washington.edu
Introduction The prevalence of Multiple Sclerosis (MS) in the United States (US) historically
has been poorly described, in part because disease activity is intermittent, making detection …

Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer.

CK Anders, E Neuberger, NRM Schwartz, K Bartley… - 2023 - ascopubs.org
1051 Background: Tucatinib (TUC) is an oral HER2-targeted therapy approved by the FDA
in Apr 2020 for use in combination with trastuzumab and capecitabine (TRA+ CAP) for …